ReviewFrontiers in medicine2018
The Non-Hemostatic Aspects of Transfused Platelets.
Review in Frontiers in medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 69 citations in OpenAlex.
- Embracing complexity in transfusion research.Vox sanguinis · 2026Review
- Platelet Transfusion for Patients with Cancer: An Update.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025Review
- Apheresis platelets modulate myeloid dendritic cell immune responses.Scientific reports · 2025Article
- Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study).Blood advances · 2024Article
- Prediction Model and Decision Analysis for Early Recognition of SDNS/FRNS in Children.Journal of inflammation research · 2024Article
- Article
- Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options.Life (Basel, Switzerland) · 2022Review
- The Predictive Value of NLR, MLR, and PLR in the Outcome of End-Stage Kidney Disease Patients.Biomedicines · 2022Article
- Platelet-derived immune-modulatory mediators and transfusion: time to consider their effects?Blood transfusion = Trasfusione del sangue · 2022Article
- Platelet-leukocyte crosstalk in COVID-19: How might the reciprocal links between thrombotic events and inflammatory state affect treatment strategies and disease prognosis?Thrombosis research · 2022Review
- Protein Concentrations in Stored Pooled Platelet Concentrates Treated with Pathogen Inactivation by Amotosalen Plus Ultraviolet a Illumination.Pathogens (Basel, Switzerland) · 2022Article
- Clinical Features and Management of COVID-19-Associated Hypercoagulability.Cardiac electrophysiology clinics · 2022Review
- Platelets as Key Factors in Inflammation: Focus on CD40L/CD40.Frontiers in immunology · 2022Review
- COVID-19 Induced Coagulopathy (CIC): Thrombotic Manifestations of Viral Infection.TH open : companion journal to thrombosis and haemostasis · 2022Article
- Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology.Frontiers in immunology · 2022Article
- Platelet in thrombo-inflammation: Unraveling new therapeutic targets.Frontiers in immunology · 2022Review
- Platelet Innate Immune Receptors and TLRs: A Double-Edged Sword.International journal of molecular sciences · 2021Review
- Review
- Inflammation-Related Markers and Thyroid Function Measures in Pediatric Patients: Is the Grade of Obesity Relevant?Diagnostics (Basel, Switzerland) · 2021Article
- Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation.Nature reviews. Cardiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelets transfusion is a safe process, but during or after the process, the recipient may experience an adverse reaction and occasionally a serious adverse reaction (SAR). In this review, we focus on the inflammatory potential of platelet components (PCs) and their involvement in SARs. Recent evidence has highlighted a central role for platelets in the host inflammatory and immune responses. Blood platelets are involved in inflammation and various other aspects of innate immunity through the release of a plethora of immunomodulatory cytokines, chemokines, and associated molecules, collectively termed biological response modifiers that behave like ligands for endothelial and leukocyte receptors and for platelets themselves. The involvement of PCs in SARs-particularly on a critically ill patient's context-could be related, at least in part, to the inflammatory functions of platelets, acquired during storage lesions. Moreover, we focus on causal link between platelet activation and immune-mediated disorders (transfusion-associated immunomodulation, platelets, polyanions, and bacterial defense and alloimmunization). This is linked to the platelets' propensity to be activated even in the absence of deliberate stimuli and to the occurrence of time-dependent storage lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.